On October 9, 2024 Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), reported a strategic collaboration with OverT Bio, a New York-based biotechnology company (Press release, Nona Biosciences, OCT 9, 2024, View Source [SID1234647117]). The collaboration will focus on developing next-generation cell therapies for solid tumors by leveraging Nona’s proprietary fully human HCAb Harbour Mice platform and its innovative direct CAR-function-based HCAb library screening platform, NonaCarFxTM.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The fully human heavy chain-only antibodies (HCAbs) generated from Nona’s HCAb Harbour Mice platform provide an ideal modality for CAR-based cell therapies. Unlike traditional methods, fully human HCAbs have the potential to significantly reduce immunogenicity. Their compact size, simplified structure, and precisely calibrated binding properties offer enhanced versatility in CAR design. In the evolving field of cell therapy, fully human HCAbs present significant potential to unlock further therapeutic advancements.
"We are excited to partner with OverT Bio to advance novel cell therapies for solid tumors," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences. "By combining our fully human HCAb technology with OverT Bio’s innovative approaches, we aim to accelerate the development of transformative therapies that have the potential to significantly improve patient outcomes."
Mat Legut, PhD, CEO of OverT Bio, added, "We are excited to partner with Nona as we are advancing the field of genetically enhanced allogeneic gamma delta T cells. By leveraging Nona’s fully human HCAbs, we are accelerating the development of our first clinical program to demonstrate the safety and efficacy of our differentiated cell engineering platforms."